These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 23190674)
1. Recent safety updates on type 2 diabetes medications: a case report and the evidence for choosing among several available drugs for this patient. Sisson EM; Mills J; Chin L Am J Nurs; 2012 Dec; 112(12):49-53. PubMed ID: 23190674 [No Abstract] [Full Text] [Related]
2. [The safety of anti-diabetic drugs in heart failure]. Frigy A; Germán-Salló M; Máthé L; Szabó M Orv Hetil; 2017 Feb; 158(5):163-171. PubMed ID: 28132538 [TBL] [Abstract][Full Text] [Related]
3. Clinical decisions. Management of type 2 diabetes. Goldberg RB; Holman R; Drucker DJ N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869 [No Abstract] [Full Text] [Related]
4. Oral diabetes medications: an update for home health clinicians. Jacobs JA; Fetzer SJ Home Healthc Nurse; 2013 Jan; 31(1):E1-13. PubMed ID: 23238625 [TBL] [Abstract][Full Text] [Related]
5. Which oral agent to use when metformin is no longer effective? Bannon M QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402 [No Abstract] [Full Text] [Related]
6. Can genetics improve precision of therapy in diabetes? Groop L; Storm P; Rosengren A Trends Endocrinol Metab; 2014 Sep; 25(9):440-3. PubMed ID: 25028244 [TBL] [Abstract][Full Text] [Related]
7. What to add in with metformin in type 2 diabetes? Petrie JR; Adler A; Vella S QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663 [TBL] [Abstract][Full Text] [Related]
8. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer. Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427 [No Abstract] [Full Text] [Related]
10. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes. Inzucchi SE Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144 [No Abstract] [Full Text] [Related]
11. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. Adler AI; Shaw EJ; Stokes T; Ruiz F; BMJ; 2009 May; 338():b1668. PubMed ID: 19465464 [No Abstract] [Full Text] [Related]
12. Pioglitazone/metformin (Actoplus met). Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136 [No Abstract] [Full Text] [Related]
13. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Deacon CF Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107 [TBL] [Abstract][Full Text] [Related]
14. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis? Olansky L Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512 [No Abstract] [Full Text] [Related]
15. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ; Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691 [No Abstract] [Full Text] [Related]
16. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes. Scherbaum WA Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977 [No Abstract] [Full Text] [Related]